The efficacy of low-dose estrogen combined with calcitonin in preventing osteoporosis

Calcitonin ile kombine edilmiş düşük-doz östrojenin osteoporozu önlemedeki etkinliği

Özet

Çalışmamızda; total abdominal hlsterektomi ve bilateral salpingo-ooforektomiyi takiben randomize olarak gruplara ayrılarak, tedavilerine başlanan 32 hastada kemik metabolizmasını monitörize etmede kullanılan biokimyasal markerler, kemik dansiteleri ve lipid profilleri değişiklikleri incelenmiştir. Sonuç olarak; 0.312 mg konjuge östrojenin, calcitoninile kombine kullanıldığında, hem menapozal semptomları gidermede, hem de osteoporozu önlemede etkili olduğu düşünülmüştür.

Abstract

OBJECTIVE: To determine the lowest dose of estrogens in combined therapy with calcitonin, necessary for cardioprotection and prevention of menopausal symptoms and osteoporosis. STUDY DESIGN: The study group consists of 32 patients who had oophorectomies for benign lesions. The study group divided into four groups. Group 1 (n=7) received 0.312 mg Ea + 1 gr calcium, group 2 (n=10) 0.312 mg E2 + 100 mill calcitonin + 1 gr calcium, group 3 (n=8) 0.625 mg E2 + 1gr calcium and group 4 (n=7) 100 mlU calcitonin + 1 gr calcium dailyjsfiar six months. In all groups, bone mass densities (BMD) measured by dual-energy x-ray absorbtidmetry (DEXA), blood and urinary levels of bone markers have been studied before and at the end of sixtnonths of therapy. RESULTS: There was no difference between 0.312 mg and 0.625 conjugated estrogen groups in relieving the vasomotor symptoms. Bone mass densities were found to be almost the same before and after therapy in all groups. In fact, there were slight increase in BMD (p>0.05) in groups 2,3,4. The most prominent fall in Z score (p<0.01) was obtained in group 2. As to the lipid profile, there wese significant decrease in cholesterol, triglyceride and LDL levels (p<0.05), and increase in HDL and VLDL levels in group 2 and 3 (p<0.05). CONCLUSION: As a result, it can be said that, 0.312 mg E2 when used in combination with calcitonin, is equally effective as 0.625 mg E2 in prevention of postmenopausal vasomotor symptoms and osteoporosis and in cardioprotection with respect to lipid profiles.